The Impact of PPAR𝜸 Genetic Variants on IBD Susceptibility and IBD Disease Course

Table 8

Haplotype and diplotype distribution in IBD cases and non-IBD controls.

	Subjects included	H1 (CC)^(a)	H2 (CT)	H3 (GC)	H4 (GT)	𝑃^(𝑐)
IBD N (%)	256	436.3 (85.2)	41.3 (8.1)	12.7 (2.5)	21.7 (4.2)	0.23
OR (C.I.)		1.27 (0.87–1.86)	0.86 (0.52–1.42)	0.5 (0.23–1.07)	1.1 (0.53–2.28)
UC N (%)	126	212.6 (84.4)	22.6 (9)	6.4 (2.5)	10.4 (4.1)	0.52
OR (C.I.)		1.19 (0.76–1.87)	0.96 (0.54–1.72)	0.51 (0.2–1.3)	1.07 (0.45–2.51)
CD N (%)	130	223.6 (86)	18.6 (7.2)	6.4 (2.5)	11.4 (4.4)	0.31
OR (C.I.)		1.36 (0.86–2.15)	0.75 (0.41–1.39)	0.49 (0.19–1.26)	1.13 (0.49–2.6)
Controls	148	242.5 (81.9)	27.5 (9.3)	14.5 (4.9)	4.5 (3.9)
		D1 (CC/CC)^(b)	D2 (CC/GT)	D3 (CC/GC)	D4 (CC/CT)
IBD N (%)	256	184.0 (71.9)	37.3 (14.6)	12.0 (4.7)	19.0 (7.4)
OR (C.I.)		1.3 (0.84–2.02)	0.86 (0.49–1.5)	0.51 (0.23–1.15)	1.24 (0.55–2.81)
UC N (%)	126	89.0 (70.6)	19.6 (15.6)	6.0 (4.8)	9.0 (7.1)
OR (C.I.)		1.23 (0.73–2.05)	0.93 (0.49–1.78)	0.52 (0.19–1.41)	1.19 (0.46–3.09)
CD N (%)	130	95.0 (73.1)	17.6 (13.5)	6.0 (4.6)	10.0 (7.7)
OR (C.I.)		1.39 (0.83–2.32)	0.79 (0.41–1.54)	0.5 (0.19–1.36)	1.29 (0.51–3.27)
Controls	148	98.0 (66.2)	24.5 (16.6)	13.0 (8.8)	9.0 (6.1)
		D5 (CT/GT)	D6 (GC/GT)	D7 (GC/CT)	D8 (GT/GT)	𝑃^(𝑐)
IBD N(%)		2.0 (0.8)	0.0 (0)	0.7 (0.3)	1.0 (0.4)	0.409
OR (C.I.)		0.58 (0.08–4.12)	—	—	—
UC N (%)		1.0 (0.8)	0.0 (0)	0.0 (0)	1.0 (0.8)	0.716
OR (C.I.)		—	—		—
CD N (%)		0.0 (0)	0.0 (0)	0.0 (0)	0.0 (0)	0.588
OR (C.I.)		—	—		—
Controls		2.0 (1.4)	1.0 (0.7)	0.5 (0.3)^(d)	0.0 (0)

OR: odds ratio; CI: confidence interval; N: absolute number; H1–H4: haplotype 1—haplotype 4; D1–D8: diplotype 1—diplotype 8; ^(a)the first base denotes the outcome at position rs1801282, the second base denotes the outcome at position rs1801282; ^(b)each base pair (before and after the slash) denotes one haplotype; ^(c)𝑃 values calculated with FAMHAP; ^(d)frequency predicted to be 0.0 when comparing UC patients with controls.